Mohammad-Reza Ardalan
1, Houshang Sanadgol
2, Hamid Nasri
3, Azar Baradaran
4, Mohammad-Reza Tamadon
5, Mahmoud Rafieian-Kopaei
6*1 Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Nephrology, Zahedan University of Medical Sciences, Zahedan, Iran.
3 Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran.
4 Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
5 Department of Nephrology, Semnan University of Medical Sciences, Semnan, Iran.
6 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
Diabetic kidney disease is a major risk of end-stage kidney failure and is associated with great morbidity and mortality, predominantly with accelerated cardiovascular disease. Current investigations have focused on the optimization of renin-angiotensin system blockade in patients with diabetic kidney disease using combinations of drugs that target this pathway, however some studies have focused on the potential of novel treatments that either target various pathways up-regulated by hyperglycemia or other targets believed to promote progression of diabetic kidney disease such as endothelin system, inflammation and vitamin D receptors. So far, a strong body of evidence supports vitamin D as a negative regulator of the circulating and local tissue renin-angiotensin system, while the renin-angiotensin system have a critical role in the physiology of sodium and volume homeostasis. The results of oral vitamin D therapy in type 2 diabetic patients are encouraging. However, more prospective interventional studies with larger duration and control of confounders are suggested
Implication for health policy/practice/research/ medical education
Diabetic kidney disease is a major risk of end-stage kidney failure and is associated with great morbidity and mortality, predominantly with accelerated cardiovascular disease. Various complex factors are related to the progression of diabetic kidney .The results of oral vitamin D therapy in type 2 diabetic patients are encouraging .However, more prospective interventional studies with larger duration and control of confounders are suggested.
Please cite this paper as: Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Vitamin D therapy in diabetic kidney disease; current knowledge on a public health problem. J Parathyr Dis 2014; 2(1): 17-19 .